Patent · US Active

Modified vitamin K dependent polypeptides

US8828939B2 · kind B2 · utility

0Cited by

5References

19Claims

0Family size

Assignee

CSL Behring AG · DE

Inventors

Thomas Weimer · Gladenbach, DE
Stefan Schulte · Marburg, DE
Kay Hofmann
Hans-Peter Hauser · Marburg, DE

Key dates

Filing date	Aug 10, 2005
Grant date	Sep 9, 2014
Priority date	—
Expiry date	Mar 5, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N9/6424
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present invention relates to modified cDNA sequences coding for vitamin K-dependent polypeptides, in particular human Factor VII, human Factor VIIa, human Factor IX and human protein C and their derivatives with improved stability and extended plasma half life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.